

Laure Gossec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4563481/publications.pdf>

Version: 2024-02-01

309
papers

23,489
citations

22153

59
h-index

9345

143
g-index

328
all docs

328
docs citations

328
times ranked

16394
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
5	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
6	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.9	743
7	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	5.0	625
8	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
9	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
10	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
11	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.9	456
12	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
13	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.9	314
14	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.9	270
15	EULAR recommendations for patient education for people with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 954-962.	0.9	247
16	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 319-326.	0.9	234
17	Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2013, 80, 29-33.	1.6	213
18	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204

#	ARTICLE	IF	CITATIONS
19	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
20	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.9	179
21	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
22	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	3.5	177
23	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
24	Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: Meta-analysis of randomized controlled trials. <i>Arthritis Care and Research</i> , 2010, 62, 984-992.	3.4	168
25	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
26	Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 206-214.	3.4	144
27	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.9	130
28	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
29	Quality of life in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 405-417.	3.0	127
30	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	0.9	123
31	Pattern of demyelination occurring during anti-TNF- α therapy: a French national survey. <i>Rheumatology</i> , 2013, 52, 868-874.	1.9	120
32	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	1.6	115
33	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 582-590.	0.9	105
34	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.9	104
35	Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology. <i>Arthritis Care and Research</i> , 2019, 71, 1336-1343.	3.4	99
36	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.9	98

#	ARTICLE	IF	CITATIONS
37	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	2.0	97
38	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
39	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000019-e000019.	3.8	90
40	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 135-150.	1.6	90
41	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
42	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn et al". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
43	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	3.4	84
44	Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2016, 68, 1767-1773.	3.4	81
45	2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2018, 85, 275-284.	1.6	80
46	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. <i>Journal of Rheumatology</i> , 2014, 41, 1025-1030.	2.0	78
47	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 203-207.	0.9	78
48	OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1432-5.	2.0	74
49	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
50	Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 533-540.	0.9	72
51	Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. <i>Journal of Rheumatology</i> , 2018, 45, 6-13.	2.0	72
52	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	8.0	71
53	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	1.9	71
54	Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review. <i>JMIR MHealth and UHealth</i> , 2019, 7, e14730.	3.7	70

#	ARTICLE	IF	CITATIONS
55	Reporting of Adherence to Medication in Recent Randomized Controlled Trials of 6 Chronic Diseases: A Systematic Literature Review. <i>American Journal of the Medical Sciences</i> , 2007, 334, 248-254.	1.1	67
56	Use of Wearable Activity Trackers to Improve Physical Activity Behavior in Patients With Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2019, 71, 758-767.	3.4	67
57	TNF alpha antagonist therapy and safety monitoring. <i>Joint Bone Spine</i> , 2011, 78, 15-185.	1.6	65
58	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	2.0	65
59	The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective – an Analysis of 2846 Patients Across 13 Countries. <i>Current Rheumatology Reports</i> , 2019, 21, 19.	4.7	63
60	Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). <i>Arthritis Research and Therapy</i> , 2012, 14, R129.	3.5	61
61	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	0.9	61
62	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	2.0	61
63	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1942-1949.	0.9	59
64	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59
65	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.9	59
66	The Impact of Coping Strategies on Mental and Physical Well-Being in Patients with Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 545-555.	3.4	58
67	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	3.4	58
68	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1436-1444.	0.9	58
69	Reliability of joint count assessment in rheumatoid arthritis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 721-729.	3.4	57
70	Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	3.4	55
71	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 69-76.	0.9	55
72	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.0	54

#	ARTICLE	IF	CITATIONS
73	Clinical outcomes in psoriatic arthritis: A systematic literature review. <i>Arthritis Care and Research</i> , 2012, 64, 397-406.	3.4	53
74	Tocilizumab: Therapy and safety management. <i>Joint Bone Spine</i> , 2010, 77, S3-S100.	1.6	52
75	An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients. <i>Joint Bone Spine</i> , 2018, 85, 709-714.	1.6	51
76	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 124-127.	0.9	51
77	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
78	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2012, 79, 3-84.	1.6	49
79	Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients. <i>Joint Bone Spine</i> , 2017, 84, 467-471.	1.6	49
80	Preliminary definitions of "flare"™ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 991-996.	0.9	48
81	Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e1.	3.7	48
82	Fatigue in psoriatic arthritis "A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	1.6	47
83	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47
84	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.9	47
85	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	2.0	46
86	Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 219-231.	2.3	44
87	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	2.4	44
88	2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. <i>Joint Bone Spine</i> , 2022, 89, 105344.	1.6	44
89	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
90	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	3.4	43

#	ARTICLE	IF	CITATIONS
91	Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2015, 82, 315-319.	1.6	41
92	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. <i>Journal of Rheumatology</i> , 2016, 43, 1300-1305.	2.0	41
93	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 715-720.	0.9	41
94	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
95	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. <i>Joint Bone Spine</i> , 2016, 83, 501-509.	1.6	39
96	Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. <i>Arthritis Care and Research</i> , 2018, 70, 1529-1535.	3.4	39
97	Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. <i>Joint Bone Spine</i> , 2019, 86, 13-19.	1.6	39
98	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39
99	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
100	Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review. <i>RMD Open</i> , 2018, 4, e000684.	3.8	37
101	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	1.9	36
102	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	1.6	35
103	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.9	35
104	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth” Content, Face, and Construct Validity. <i>Journal of Rheumatology</i> , 2014, 41, 1000-1004.	2.0	34
105	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	4.7	34
106	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
107	Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study. <i>RMD Open</i> , 2017, 3, e000434.	3.8	34
108	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34

#	ARTICLE	IF	CITATIONS
109	Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patients. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 78.	2.4	32
110	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 293-303.	0.9	32
111	The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. <i>Rheumatology</i> , 2018, 57, 300-308.	1.9	31
112	Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14351.	3.7	31
113	Safety of biologics: Elaboration and validation of a questionnaire assessing patients' self-care safety skills: The BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section. <i>Joint Bone Spine</i> , 2013, 80, 471-476.	1.6	30
114	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001004.	3.8	30
115	Response to: "Comment on: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al. by Wei et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139.	0.9	30
116	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.9	30
117	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.9	30
118	Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. <i>Advances in Rheumatology</i> , 2018, 58, 1.	1.7	29
119	Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative. <i>Journal of Rheumatology</i> , 2015, 42, 2496-2502.	2.0	28
120	Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1661-1666.	0.9	28
121	Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health. <i>Journal of Rheumatology</i> , 2017, 44, 193-200.	2.0	28
122	Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort. <i>RMD Open</i> , 2018, 4, e000657.	3.8	28
123	Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. <i>Rheumatology</i> , 2020, 59, 1818-1825.	1.9	28
124	Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). <i>Clinical Rheumatology</i> , 2021, 40, 2753-2761.	2.2	28
125	Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients. <i>Rheumatology International</i> , 2016, 36, 1711-1718.	3.0	27
126	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	2.0	27

#	ARTICLE	IF	CITATIONS
127	Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA). <i>Joint Bone Spine</i> , 2019, 86, 55-60.	1.6	27
128	The EULAR Outcome Measures Library: an evolutionary database of validated patient-reported instruments. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 475-476.	0.9	26
129	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. <i>Rheumatology</i> , 2016, 55, 735-744.	1.9	26
130	Big Data and artificial intelligence: Will they change our practice?. <i>Joint Bone Spine</i> , 2020, 87, 107-109.	1.6	26
131	Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1036-1041.	0.9	25
132	Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-sectional Study of 977 Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1504-1509.	3.4	25
133	Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. <i>Joint Bone Spine</i> , 2018, 85, 405-410.	1.6	25
134	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , 2021, 17, 11-15.	8.0	25
135	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	3.9	25
136	Influence of sex on disease severity in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1448-51.	2.0	25
137	Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 664-70.	0.8	25
138	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 32-40.	3.8	24
139	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
140	Relative Clinical Influence of Clinical, Laboratory, and Radiological Investigations in Early Arthritis on the Diagnosis of Rheumatoid Arthritis. Data from the French Early Arthritis Cohort ESPOIR. <i>Journal of Rheumatology</i> , 2010, 37, 2486-2492.	2.0	23
141	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019, 58, 1649-1654.	1.9	23
142	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	3.8	23
143	Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. <i>Rheumatology</i> , 2014, 53, 1274-1281.	1.9	22
144	Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-sectional Multicenter Study. <i>Arthritis Care and Research</i> , 2016, 68, 638-644.	3.4	22

#	ARTICLE	IF	CITATIONS
145	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	3.4	22
146	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	2.0	21
147	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). <i>Rheumatology</i> , 2021, 60, 888-895.	1.9	21
148	Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scale. <i>Rheumatology</i> , 2012, 51, 333-337.	1.9	20
149	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	2.0	20
150	Treatment of psoriatic arthritis: management recommendations. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S73-7.	0.8	20
151	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, 213.	3.5	19
152	Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. <i>Joint Bone Spine</i> , 2016, 83, 427-431.	1.6	19
153	Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212612.	0.9	19
154	Gender equity in clinical practice, research and training: Where do we stand in rheumatology?. <i>Joint Bone Spine</i> , 2019, 86, 669-672.	1.6	19
155	Updating the OMERACT Filter: Discrimination and Feasibility. <i>Journal of Rheumatology</i> , 2014, 41, 1005-1010.	2.0	18
156	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	0.9	18
157	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783.	0.9	18
158	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , 2020, 59, 1495-1504.	1.9	18
159	The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 583-585.	3.4	18
160	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.9	18
161	Fatigue in Egyptian patients with rheumatic diseases: a qualitative study. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 134.	2.4	17
162	Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. <i>International Journal of Cardiology</i> , 2015, 183, 149-154.	1.7	17

#	ARTICLE	IF	CITATIONS
163	Mucopolysaccharidoses seen in adults in rheumatology. <i>Joint Bone Spine</i> , 2017, 84, 663-670.	1.6	17
164	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
165	Evaluation of the performances of "typical" imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study. <i>RMD Open</i> , 2019, 5, e000918.	3.8	17
166	Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020?. <i>Sensors</i> , 2020, 20, 4797.	3.8	17
167	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.9	17
168	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. <i>Arthritis Research and Therapy</i> , 2017, 19, 118.	3.5	16
169	Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 258-263.	0.9	16
170	EULAR "points to consider" for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16
171	Wearable activity trackers and artificial intelligence in the management of rheumatic diseases. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 928-935.	1.0	16
172	Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?. <i>RMD Open</i> , 2022, 8, e002131.	3.8	16
173	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: ³-Year Results From a Phase IIb Randomized Controlled Trial and Its ^{Open}-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1959-1970.	5.6	16
174	Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients. <i>Journal of Rheumatology</i> , 2017, 44, 425-430.	2.0	15
175	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	2.0	15
176	OPO235...SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL. , 2019, , .		15
177	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. <i>Journal of Rheumatology</i> , 2014, 41, 1016-1024.	2.0	14
178	The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 154-159.	1.6	14
179	Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 473-476.	1.6	14
180	Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients. <i>Joint Bone Spine</i> , 2019, 86, 747-752.	1.6	14

#	ARTICLE	IF	CITATIONS
181	Response to: "Correspondence on EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Fallon et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e174-e174.	0.9	14
182	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	1.6	14
183	Patient-Reported Outcomes in Rheumatoid Arthritis: Why are They Important and How Should They Be Assessed?. <i>Turkish Journal of Rheumatology</i> , 2010, 25, 99-104.	0.2	13
184	Autonomous online health assessment questionnaire registry in daily clinical practice. <i>Rheumatology</i> , 2013, 52, 883-887.	1.9	13
185	Repeated Anticitrullinated Protein Antibody and Rheumatoid Factor Assessment Is Not Necessary in Early Arthritis: Results from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 41-46.	2.0	13
186	Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. <i>Rheumatology</i> , 2016, 55, 1009-1016.	1.9	13
187	Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 974-978.	2.0	13
188	Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid Arthritis Study) randomised controlled trial. <i>RMD Open</i> , 2017, 3, e000474.	3.8	13
189	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1503-1510.	2.2	13
190	Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response" results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 190.	3.5	13
191	Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches. <i>Joint Bone Spine</i> , 2020, 87, 405-411.	1.6	13
192	Cross-sectional study of self-care safety skills in 677 patients on biodrugs for inflammatory joint disease. <i>Joint Bone Spine</i> , 2014, 81, 502-507.	1.6	12
193	Commentary: Patients as Partners: Building on the Experience of Outcome Measures in Rheumatology. <i>Arthritis and Rheumatology</i> , 2016, 68, 1334-1336.	5.6	12
194	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.4	12
195	Assessing structural changes in axial spondyloarthritis using a low-dose biplanar imaging system. <i>Rheumatology</i> , 2014, 53, 1669-1675.	1.9	11
196	Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. <i>RMD Open</i> , 2018, 4, e000619.	3.8	11
197	Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 2085-2095.	3.0	11
198	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	3.4	11

#	ARTICLE	IF	CITATIONS
199	Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 26-31.	0.8	11
200	Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1311-1321.	3.0	11
201	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 3257-3268.	1.9	11
202	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 303-312.	0.0	10
203	Brief Report: Nonsteroidal Antiinflammatory Drug "Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 2363-2368.	5.6	10
204	A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study. <i>Rheumatology</i> , 2015, 54, 1161-1169.	1.9	10
205	Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial. <i>Joint Bone Spine</i> , 2017, 84, 577-581.	1.6	10
206	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10
207	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Results of Two Phase III Randomized Controlled Trials. <i>Arthritis Care and Research</i> , 2022, 74, 759-767.	3.4	10
208	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	3.8	10
209	Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. <i>RMD Open</i> , 2021, 7, e001517.	3.8	10
210	Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 915.	1.9	10
211	Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 505-13.	0.8	10
212	Mentoring of young professionals in the field of rheumatology in Europe: results from an EMerging Eular NETwork (EMEUNET) survey. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 935-41.	0.8	10
213	Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. <i>Joint Bone Spine</i> , 2015, 82, 451-454.	1.6	9
214	Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 79-82.	1.6	9
215	Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients. <i>Joint Bone Spine</i> , 2017, 84, 163-168.	1.6	9
216	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. <i>Journal of Rheumatology</i> , 2019, 46, 1259-1267.	2.0	9

#	ARTICLE	IF	CITATIONS
217	Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. <i>Rheumatology International</i> , 2019, 39, 141-146.	3.0	9
218	Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort. <i>Arthritis Care and Research</i> , 2020, 73, 1300-1305.	3.4	9
219	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
220	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. <i>Rheumatology</i> , 2023, 62, 617-628.	1.9	9
221	Patient perspective in outcome measures developed by OMERACT. <i>Indian Journal of Rheumatology</i> , 2013, 8, S17-S22.	0.4	8
222	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	2.0	8
223	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. <i>Quality of Life Research</i> , 2018, 27, 2909-2921.	3.1	8
224	Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients. <i>Joint Bone Spine</i> , 2019, 86, 610-614.	1.6	8
225	Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1835-1836.	0.9	7
226	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. <i>RMD Open</i> , 2019, 5, e000914.	3.8	7
227	Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. <i>Rheumatology</i> , 2019, 58, 1498-1499.	1.9	7
228	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
229	Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 888-894.	3.4	7
230	Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. <i>RMD Open</i> , 2022, 8, e001986.	3.8	7
231	Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1149-1154.	2.2	6
232	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020, 59, 3458-3467.	1.9	6
233	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.9	6
234	Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 209-213.	0.8	6

#	ARTICLE	IF	CITATIONS
235	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	1.9	6
236	Impact of repeated measures of joint space width on the sample size calculation: An application to hip osteoarthritis. <i>Joint Bone Spine</i> , 2015, 82, 172-176.	1.6	5
237	Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies. <i>Joint Bone Spine</i> , 2016, 83, 101-103.	1.6	5
238	Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. <i>RMD Open</i> , 2017, 3, e000514.	3.8	5
239	The controversy of using PGA to define remission in RA. <i>Nature Reviews Rheumatology</i> , 2018, 14, 245-245.	8.0	5
240	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. <i>Advances in Rheumatology</i> , 2018, 58, 33.	1.7	5
241	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. <i>Joint Bone Spine</i> , 2021, 88, 105071.	1.6	5
242	Patients'™ safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire. <i>Joint Bone Spine</i> , 2021, 88, 105215.	1.6	5
243	Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 786-790.	0.8	5
244	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatologica Portuguesa</i> , 2018, 43, 52-60.	0.2	5
245	Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001828.	3.8	5
246	Is the widely-used score in axial spondyloarthritis, Bath Ankylosing Spondylitis Disease Activity Index, influenced by patients'™ optimism? A cross-sectional study of 206 patients. <i>Joint Bone Spine</i> , 2017, 84, 629-630.	1.6	4
247	Criteria for inclusion in programs of functional restoration for chronic low back pain: Pragmatic Study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 189-194.	2.3	4
248	Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 84-89.	1.9	4
249	Effectiveness of a short functional restoration program for patients with chronic low back pain: A cohort study of 193 patients. <i>Joint Bone Spine</i> , 2020, 87, 640-646.	1.6	4
250	What influences patients'™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	1.9	4
251	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 2054-2062.	1.9	4
252	Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 1785-1795.	3.0	4

#	ARTICLE	IF	CITATIONS
253	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
254	Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2361-2368.	2.0	3
255	Development and validation of a questionnaire categorizing behavioral strategies in patients with chronic low back pain. <i>Joint Bone Spine</i> , 2017, 84, 725-731.	1.6	3
256	Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 6-14.	2.0	3
257	To apply the recent EULAR recommendations, more knowledge on adherence patterns to medication and to physical activity is needed. <i>Joint Bone Spine</i> , 2021, 88, 105137.	1.6	3
258	Fluctuation of pain is frequent in rheumatoid arthritis and axial spondyloarthritis: a 12 weeks prospective study of 165 patients. <i>Joint Bone Spine</i> , 2021, 89, 105306.	1.6	3
259	Actualisation 2022 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2022, 89, 210-222.	0.0	3
260	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e183-e183.	0.9	3
261	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. <i>Joint Bone Spine</i> , 2022, , 105372.	1.6	3
262	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. <i>Rheumatology and Therapy</i> , 0, , .	2.3	3
263	Defining and managing flares in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2022, 34, 195-202.	4.3	3
264	Monitoring of Disease and Treatment of Patients With Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, , 97-125.	0.1	2
265	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
266	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
267	Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. <i>Clinical Rheumatology</i> , 2021, 40, 4943-4954.	2.2	2
268	Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 82-7.	0.8	2
269	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3182-3185.	6.7	1
270	La place de la e-santé et les objets connectés dans le traitement de patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 66-70.	0.0	1

#	ARTICLE	IF	CITATIONS
271	Response to: "The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies" by Tillet et al. Annals of the Rheumatic Diseases, 2018, 77, e24-e24.	0.9	1
272	Reply to the comment of Alkan Melikoglu "Joint manifestations can provide diagnostic clues in Morquio syndrome, a case report". Joint Bone Spine, 2019, 86, 123-124.	1.6	1
273	Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain. Arthritis Research and Therapy, 2019, 21, 63.	3.5	1
274	Recommandations pour l'évaluation et l'optimisation de l'adhésion aux traitements de fond médicamenteux des rhumatismes inflammatoires chroniques: un processus basé sur des revues de la littérature et un consensus d'experts. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 555-562.	0.0	1
275	Self-reported competencies and educational needs of rheumatology nurses: Results of a national survey. Joint Bone Spine, 2020, 87, 91-93.	1.6	1
276	Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings. Rheumatology, 2022, 61, 2603-2608.	1.9	1
277	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the <scp>28</scp> Joint Disease Activity Score, C-reactive protein level and patient global assessment" by Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	2.1	1
278	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. RMD Open, 2021, 7, e001962.	3.8	1
279	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	1.9	1
280	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. International Journal of Clinical Rheumatology, 2014, 9, 327-339.	0.3	0
281	Étude transversale des compétences de santé de 677 patients traités par biomédicament pour un rhumatisme inflammatoire. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 29-34.	0.0	0
282	Introduction. Journal of Rheumatology, 2015, 42, 1926-1930.	2.0	0
283	Functional restoration programs in patients with chronic low back pain and body composition: No change in muscle mass assessed through Dual X-ray absorptiometry in 94 patients, a monocenter longitudinal study. Joint Bone Spine, 2016, 83, 741-742.	1.6	0
284	Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab: Évaluation ouverte de 175 patients. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 457-460.	0.0	0
285	Collecte et prise en charge de certaines comorbidités et facteurs de risque associés dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 123-131.	0.0	0
286	Développement et validation d'un questionnaire identifiant différentes stratégies comportementales chez les patients lombalgiques chroniques. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 381-387.	0.0	0
287	La rémission est associée à la CRP et au tabagisme dans la spondyloarthrite axiale débutante. La cohorte DESIR. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 178-182.	0.0	0
288	Perception des poussées de polyarthrite rhumatoïde de telles que rapportées par les patients: sous-analyse de l'essai STRASS sur les stratégies de diminution progressive du traitement. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 353-358.	0.0	0

#	ARTICLE	IF	CITATIONS
289	Le délai diagnostique de la spondyloarthrite axiale: Étude transversale sur 432 patients. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 183-187.	0.0	0
290	Knowledge of and expectations about functional restoration programs for chronic low back pain: A mirror survey of 150 patients and 80 physicians in 2017. Joint Bone Spine, 2019, 86, 812-813.	1.6	0
291	Effet des traitements biologiques sur la fatigue dans le rhumatisme psoriasique: revue systématique de la littérature et méta-analyse. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 420-425.	0.0	0
292	THU0642...EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
293	SAT0367...PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
294	FRI0720-HPR...DEVELOPMENT AND VALIDATION OF A SELF-ADMINISTRATED QUESTIONNAIRE MEASURING ESSENTIAL KNOWLEDGE FOR PATIENTS WITH RHEUMATOID ARTHRITIS: THE RHEUMATOID ARTHRITIS ASSESSMENT KNOWLEDGE QUESTIONNAIRE (RAKE). , 2019, , .		0
295	Compétences et besoins éducatifs rapportés par les infirmiers de rhumatologie: résultats d'une enquête nationale française. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 314-316.	0.0	0
296	Agreement with the French 2019 recommendations on treatment adherence in rheumatic diseases among 357 health professionals. Joint Bone Spine, 2020, 87, 513-515.	1.6	0
297	Accord de 357 professionnels de santé avec les recommandations des Rencontres des Experts 2019 sur l'adhésion médicamenteuse. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 159-161.	0.0	0
298	Critères d'évaluation à collecter pour optimiser la prise en charge de routine de la spondyloarthrite axiale: proposition fondée sur des preuves et une rencontre des experts. Revue Du Rhumatisme (Edition) Tj ETQ 0 0 0 rgBT /Overlo	0.0	0
299	The adherence questionnaires in chronic inflammatory rheumatic diseases and their psychometric properties: A systematic literature review. Joint Bone Spine, 2021, 88, 105160.	1.6	0
300	Numérique et activités physiques en rhumatologie. Revue Du Rhumatisme Monographies, 2021, 88, 237-242.	0.0	0
301	Les questionnaires d'adhésion aux traitements de fond dans les rhumatismes inflammatoires chroniques et leurs propriétés psychométriques: une revue systématique de la littérature. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 469-469.	0.0	0
302	Response to: "Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases". Screening for comorbidities: what is the remit of rheumatologists?. Annals of the Rheumatic Diseases, 2016, 75, e56-e56.	0.9	0
303	Évaluation des compétences de sécurité des patients vis-à-vis des biothérapies et inhibiteurs de JAK: actualisation du questionnaire BioSecure. Revue Du Rhumatisme (Edition Francaise), 2021, 89, 187-187.	0.0	0
304	Prediction of Work Impact in Axial Spondylarthritis by the Work Instability Scale: A Prospective Cohort Study Of 101 Patients. Journal of Rheumatology, 2021, 48, jrheum.191397.	2.0	0
305	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	3.4	0
306	Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis. Lancet Rheumatology, The, 2022, 4, e159-e160.	3.9	0

#	ARTICLE	IF	CITATIONS
307	Concomitant therapies as an outcome measure. Part 1: Drugs. Journal of Rheumatology, 2005, 32, 2447-8.	2.0	0
308	P260â€fSecukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial. Rheumatology, 2022, 61, ..	1.9	0
309	Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France. Journal of Rheumatology, 2022, 49, 1176-1178.	2.0	0